<div><p><b>Background: </b>The gut-liver interaction has emerged as a critical component in alcohol-associated liver disease (ALD) pathogenesis. The central mediators are the gut luminal antigens, especially endotoxins that translocate to the liver. This occurs because of (i) compromised gut barrier integrity due to epithelial tight junction (TJ) disruption; and (ii) qualitative/quantitative gut microbiota changes and increased production of pathogenic antigens.</p>

<div><p><strong><b>Background:</strong> </b>Liver fibrosis is the consequence of chronic liver diseases that can progress to cirrhosis and liver failure. However, the role and mechanism of gut leakiness in liver fibrosis are poorly understood, and there is no FDA-approved drug to treat liver fibrosis.

<div><p><b>Background:</p> </b><p>Biliary atresia (BA) is the principal indication for liver transplantation in children, yet there is little information regarding its underlying etiology. Recent data strongly places BA as a developmental cholangiopathy suggesting that there are gene variant contributions that can be discovered using modern gene sequencing and analytical technologies.

<div><p><strong><b>Background:</strong> </b>Early recurrence of hepatocellular carcinoma (HCC) after surgical resection compromises patient survival. Timely detection of minimal residual tumor is helpful in recurrence monitoring and evaluating treatment strategies. This study examined the feasibility of virus-host chimera DNA (vh-DNA) generated from integration sites of hepatitis B virus (HBV) in the HCC chromosome as a personalized circulating biomarker for residual tumors after surgery.</p>

<div><p><b>Background:</p> </b><p>To develop a non-invasive multivariate models based on Three-dimensional MR elastography (3D-MRE) to determine portal hypertension (PH), particularly to diagnose clinically significant portal hypertension (CSPH, HVPG&gt;10mmHg) and severe portal hypertension (SPH, HVPG&gt;12mmHg), using HVPG as the gold standard.</p>

<div><p><b>Background: </b>Initial recommendations from scientific societies cautioned against procurement of livers from COVID-19(+) donors. Growing evidence supports the short-term safety of liver transplantation from COVID-19(+) donors. We described usage of liver transplants from COVID-19(+) donors during the COVID-19 pandemic and characterized associated transplant outcomes using data from the United Network for Organ Sharing registry.</p>

<div><p><b>Background: </b>Telemedicine removes geographic and temporal obstacles to healthcare access. Few randomized trials have evaluated telemedicine effectiveness for underserved populations. We compared sustained virological response (SVR12) rates for hepatitis C virus (HCV) infection among persons with opioid use disorder through facilitated telemedicine (FTM) versus offsite liver specialist referral (usual care or UC).</p>

<div><p><b>Background: </b>Retatrutide (RETA; LY3437943) is a novel triple agonist of the GIP, GLP-1 and glucagon receptors under investigation for obesity treatment. A 48-week phase 2 obesity study demonstrated weight loss of −22.8% and −24.2% with RETA 8 and 12 mg. We report effects of RETA on liver fat (LF) and correlations with metabolic measures in subjects with MASLD included in this trial.</p>

<div><p><b>Background: </b>HBV and HIV are both major global health concerns as HBV infects 296 million people while HIV infects 38 million individuals worldwide.HIV/HBV co-infection is common due to similar routes of transmission, with an estimated 10% of HIV-infected individuals also infected with HBV. HIV/HBV co-infected individuals progress to chronic HBV infection more frequently and exhibit reduced HBV-specific T cell responses, with a higher probability of extensive liver fibrosis and hepatocellular carcinomas.

<div><p><strong>Background</strong>: Quality of life and symptom management are important for patients with chronic liver disease (CLD), which can precede cirrhosis development. CLD patients with/without cirrhosis have mood disorders which affect cognition. Cognitive impairment is testing using simple (Animal naming, ANT) or more complicated [Stroop and Psychometric hepatic encephalopathy score (PHES)] but their impact on QOL across the spectrum of CLD is unclear.